Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03990883 · ClinicalTrials.gov registry record · NA
Effectiveness and Safety of Princess FILLER Lidocaine in Correction of Nasolabial Folds (NLF)
A NA study of Dermatological Non-Disease, sponsored by Croma-Pharma.
- Completed
- Registry status
- NA
- Development phase
- 295
- Enrollment target
- 11
- Study locations
NCT03990883: Completed NA study of Dermatological Non-Disease, sponsored by Croma-Pharma.
NCT03990883 is a NA study of Dermatological Non-Disease that has completed, run by Croma-Pharma. The registered enrollment target is 295 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (79% lower). The trial reports 11 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03990883, a NA study of Dermatological Non-Disease, has completed, sponsored by Croma-Pharma.
- COMPLETED
- Registry status
- NA
- Development phase
- 295 participants
- Enrollment target
- 11
- Study locations
Study Summary
Clinical Investigation to demonstrate the effectiveness and safety of Princess Filler Lidocaine in the correction of moderate to severe nasolabial folds
Primary Outcome
The percentage of responders based on the independent blinded evaluating investigator live assessment at Week 24 after initial treatment and compared to Juvederm® Ultra XC. Responder is defined as having at least one grade improvement over Baseline, on the 5-point Nasolabial Folds-Severity Rating Scale (NLF-SRS). NLF-SRS scores are ranked as 0 (None/minimal), 1 (Mild), 2 (Moderate), 3 (Severe) and 4 (Extreme). Hierarchical Testing Procedure: This primary outcome measure is assessed first in a
Conditions Studied
Interventions
- DEVICE Princess Filler Lidocaine
Study Locations (11)
California
- John Joseph - Beverly Hills
- Sabrina Fabi - San Diego
- Ava Shamban - Santa Monica
Alabama
- Gary Monheit - Birmingham
Colorado
- Joel Cohen - Greenwood Village
Florida
- Jeremy Green - Coral Gables
Maryland
- Robert Weiss - Hunt Valley
New Jersey
- Jeanine Downie - Montclair
New York
- The Center for Dermatology Cosmetic and Laser Surgery - New York
Pennsylvania
- Susan Taylor - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 295 participants |
| Start Date | 2019-06-04 |
| Est. Completion | 2022-02-15 |
| Phase | NA |
What the finished NCT03990883 record still lists
NCT03990883 is an interventional study that assigns participants to a tested intervention. The registered 295 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (79% lower).
The record links to 1 condition, with Dermatological Non-Disease appearing as the primary indexed condition, and to 1 intervention - of which Princess Filler Lidocaine is the first listed.
NCT03990883 lists 11 locations in 9 states (California, Alabama, Colorado).
Frequently Asked Questions
What is clinical trial NCT03990883 about?
NCT03990883 is a clinical study titled "Effectiveness and Safety of Princess FILLER Lidocaine in Correction of Nasolabial Folds (NLF)". Clinical Investigation to demonstrate the effectiveness and safety of Princess Filler Lidocaine in the correction of moderate to severe nasolabial folds
What is the current status of trial NCT03990883?
This trial is currently completed. It is a NA study. The enrollment target is 295 participants. The study started on 2019-06-04. Estimated completion is 2022-02-15.
What conditions does trial NCT03990883 study?
This clinical trial studies the following conditions: Dermatological Non-Disease.
What interventions are being tested in trial NCT03990883?
The interventions under investigation include: Princess Filler Lidocaine (DEVICE).
Who is sponsoring clinical trial NCT03990883?
This trial is sponsored by Croma-Pharma, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03990883 being conducted?
This trial has 11 study locations across Alabama, California, Colorado, Florida, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Dermatological Non-Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03990883's enrollment target sits among peer trials
295 373rd of 2000 higher than 1,628 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05201781 · 295 participants · Phase 4
A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
- NCT06004245 · 295 participants · Phase 1
A Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of VVD-133214 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors
- NCT06494111 · 295 participants · Phase 2
Systemic Therapy of Open-label Prophylactic Pravastatin or Pentoxifylline/Tocopherol Prevention of Lymphedema Advancing to Eventual Fibrosis: an Interventional Registry-embedded Bayesian Randomized Trial for Radiation Sequelae (STOP4-LATE-FIBROSE)
- NCT07020221 · 295 participants · Phase 1
A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI